Video

Dr. Vokes Discusses Unanswered Questions from the PACIFIC Trial in NSCLC

Everett E. Vokes, MD, discusses unanswered questions from the phase III PACIFIC trial in stage III non–small cell lung cancer.

Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses unanswered questions from the phase III PACIFIC trial in stage III non—small cell lung cancer (NSCLC).

Durvalumab (Imfinzi) has become standard of care for patients with unresectable stage III NSCLC who do not progress on concurrent chemoradiation based on the results of the PACIFIC trial. In the trial, patients who received chemoradiation followed by durvalumab experienced a significant improvement in progression-free survival and overall survival versus patients who received chemoradiation followed by placebo.

In a subset analysis, patients who received durvalumab within 2 weeks of completing concurrent chemoradiation appeared to derive additional benefit, explains Vokes. However, the patients who were able to start durvalumab in this timeframe may be fitter patients overall. Additional research is needed to determine whether starting durvalumab early is beneficial to patients.

Moreover, sequencing strategies need to be further explored as patients could benefit from receiving durvalumab in the neoadjuvant setting or concurrently with chemoradiation.

Lastly, it is unknown whether patients with EGFR mutations derived the same benefit from the regimen as patients in the total population. Although patients with EGFR mutations were included in this trial, the subset was too small to draw conclusions from, says Vokes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center